PRE-MARKET | October 07, 2016 | $EXEL, $AMZN, $GS, $FSLR, $HON, $DB, $TOT, $TWTR

PRE-MARKET MOVERS

 

UPGRADES

 

DOWNGRADES

 

Trending Social Alerts

1. GWPH:Goldman upgrades SMID biotech to attractive. $GWPH initiated buy at GS with $189/target

2. CLVS:$CLVS down 8% –> Rucaparib 0% ORR for platinum-refractory patients, 25% ORR for platinum-resistant patients

3. SCYX:$SCYX upgraded to Strong Buy at WBB Securities.

4. CDTX:$CDTX Cidara Therapeutics Announces Commencement of Public Offering of Common Stock Read more:

5. RL:$RL Goldman Sachs Adds Ralph Lauren to Conviction Buy List, $120 PT

6. INCY:$INCY – epacadostat + Keytruda in melanoma PFS rate of 74% at 6 mos., 57% at 12 mos. mPFS not yet reached. Median follow up 56 wks. #ESMO17

7. ABUS:$ABUS CMO and Managing Directors AXED after embarrassing trial results last week: cc: @egomaniakos

8. ALNY:MS $ALNY Revusiran Discontinuation Raises Key Questions; Downgrading PT $36.00 Imbalance of mortality leads

9. SAGE:@tgtxdough Renewed interest in CNS disorders has created a rich pipeline of new candidates Names recommend $AVXS $GWPH $SAGE

10. KITE:@tgtxdough Immuno-oncology continues to emerge as a cornerstone of cancer treatment. Names recommend $INCY $KITE

 

Trending News Headlines

1. Andy Biotech on Twitter

“$CLVS down 8% –> Rucaparib 0% ORR for platinum-refractory patients, 25% ORR for platinum-resistant patients”

2. Clovis Oncology Presents Efficacy and Safety Data from New Drug Application (NDA) Population for Rucaparib in the Treatment of Advanced Mutant BRCA Ovarian Cancer at 2016 ESMO Congress | Business Wire

Clovis Oncology (NASDAQ:CLVS) announced today the oral presentation of the primary efficacy and safety data from its NDA dataset for rucaparib at

3. Liquid Biopsy on Twitter

“$INCY $MRK #ESMO16 Update – Thoughts on ECHO-202/KEYNOTE-037 Initial melanoma PFS trend look competitive vs. (cont)

4. Payrolls in U.S. Rise 156,000 as Americans Stream Into Workforce

Employers continued to add to payrolls in September as record openings drew more Americans into the workforce and most found jobs, indicating the U.S. labor market is settling into a pace that will support the economy.

5. Data Presented at ESMO 2016 Adds to Understanding of Abraxane® as a Therapy for Patients with Historically Challenging Solid Tumors (NASDAQ:CELG)

Multiple presentations evaluate ABRAXANE alone or in combination with novel agents and novel regimens to treat mPAC, NSCLC, and MBC SUMMIT, N.J.–(BUSINESS WIRE)– …

6. Bridge and Tunnel Investor

Visit our forum at: bridgeandtunnelinvestor.com

7. Ruby Tuesday, Inc. (NYSE:RT) – Ruby Tuesday Q1 Sales Decline, Closes 95 Stores In Quarter

Shares of Ruby Tuesday, Inc. (NYSE: RT) are down following the release of its Q1 earnings after Thursday’s market close. The restaurant operator’s total revenue…

Technology News